We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BI’s Idarucizumab Immediately Reverses Dabigatran in Phase 3 Study
BI’s Idarucizumab Immediately Reverses Dabigatran in Phase 3 Study
An interim Phase 3 analysis of idarucizumab shows the drug reverses the anticlotting effect of Pradaxa within minutes in patients requiring urgent procedures or with serious bleeding complications, Boehringer Ingelheim reports.